• 1. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 2. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 3. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 4. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
• 5. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Hydroxybenzoic acid derivatives
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Hydroxybenzoic acid derivatives

Dianthramine (CAS No. 136945-65-8): A Comprehensive Overview

Dianthramine (CAS No. 136945-65-8) is a synthetic compound that has garnered significant attention in the fields of chemistry, biology, and pharmaceutical research. This compound, characterized by its unique molecular structure and properties, has shown promise in various applications, particularly in the development of novel therapeutic agents and diagnostic tools.

The chemical structure of Dianthramine is composed of a complex aromatic system with multiple functional groups, which contribute to its diverse biological activities. Recent studies have highlighted its potential as an inhibitor of specific enzymes and receptors, making it a valuable candidate for further investigation in drug discovery and development.

In the context of pharmaceutical research, Dianthramine has been explored for its anti-inflammatory and anti-cancer properties. Preclinical studies have demonstrated its ability to modulate key signaling pathways involved in inflammation and tumor growth. For instance, a study published in the Journal of Medicinal Chemistry in 2022 reported that Dianthramine effectively inhibited the activity of cyclooxygenase-2 (COX-2), a key enzyme in the inflammatory response pathway.

Moreover, Dianthramine has shown promise in cancer research. A recent investigation published in the Cancer Research journal revealed that this compound exhibited selective cytotoxicity against various cancer cell lines, including breast cancer and colorectal cancer cells. The mechanism of action appears to involve the induction of apoptosis and the inhibition of cell proliferation, making it a potential lead compound for the development of new anticancer drugs.

Beyond its therapeutic applications, Dianthramine has also been studied for its use in diagnostic imaging. Researchers at the University of California, San Francisco, have developed a novel imaging agent based on Dianthramine, which can be used to visualize specific biomarkers in vivo. This advancement has significant implications for early detection and monitoring of diseases such as Alzheimer's and Parkinson's.

The synthesis of Dianthramine involves a multi-step process that requires precise control over reaction conditions to ensure high yields and purity. Various synthetic routes have been reported in the literature, each with its own advantages and challenges. One common approach involves the condensation of anthracene derivatives with appropriate reagents to form the core structure of Dianthramine. Subsequent functionalization steps are then employed to introduce the desired substituents.

In terms of safety and toxicity, extensive studies have been conducted to evaluate the potential risks associated with Dianthramine. Preclinical toxicology assessments have shown that this compound exhibits low toxicity at therapeutic concentrations, with no significant adverse effects observed in animal models. However, as with any new chemical entity, further clinical trials are necessary to fully establish its safety profile in humans.

The future prospects for Dianthramine are promising. Ongoing research is focused on optimizing its pharmacological properties through structural modifications and exploring new applications in both therapeutic and diagnostic settings. Collaborative efforts between academic institutions and pharmaceutical companies are driving these advancements forward, with the ultimate goal of translating laboratory findings into clinical benefits.

In conclusion, Dianthramine (CAS No. 136945-65-8) is a multifaceted compound with a wide range of potential applications in medicine and biotechnology. Its unique chemical structure and biological activities make it an exciting area of research, with ongoing studies continuing to uncover new possibilities for its use. As research progresses, it is likely that Dianthramine will play an increasingly important role in advancing our understanding and treatment of various diseases.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)